<DOC>
	<DOCNO>NCT00128310</DOCNO>
	<brief_summary>The investigator assume progression-free survival mean time patient treat vinorelbine 3 month , patient treat gemcitabine plus vinorelbine 5 month . That imply reduction risk ratio 40 % ( Hazard ratio = 1,67 ) . Assuming bilateral alpha error 0.05 beta error 10 % , number event need 60 % patient progress 1 year , number patient need per treatment arm 114 . Considering 10 % post-randomization drop-out , final number patient 252 ( 126 per arm ) .</brief_summary>
	<brief_title>Vinorelbine Versus Gemcitabine Plus Vinorelbine Metastatic Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<criteria>Histological cytological diagnosis breast cancer , metastasis . Metastatic lesion curable surgery radiotherapy . Women age &gt; 18 . To receive previous treatment anthracyclines taxanes . A maximum 2 previous chemotherapy treatment line metastatic disease . Previous radiotherapy allow , whenever radiate area disease location . At least 4 week since last previous antineoplastic treatment ; patient must recover previous toxicity . Performance status &lt; 2 World Health Organization ( WHO ) scale . Clinically measurable , non measurable really non measurable disease , per Response Evaluation Criteria Solid Tumors ( RECIST ) criterion . Life expectancy least 12 week . Patients able comply receive adequate followup . Adequate bone marrow function : neutrophil ≥ 2 x 10^9/L ; platelet ≥ 100 x 10^9/L ; hemoglobin ≥ 100 g/L . Calcium within normal limit . Premenopausal woman must adopt adequate contraceptive method study 3 month treatment finalization . Active infection serious concomitant disease ( investigator ’ criterion ) . Clinical evidence metastasis central nervous system ( CNS ) . Blastic bone lesion disease . Previous neurological toxicity grade 34 ( National Cancer InstituteCommon Toxicity Criteria [ NCICTC ] v.2.0 ) . Previous treatment gemcitabine and/or vinorelbine . More 2 previous chemotherapy treatment line metastatic disease . Abnormal liver function ( bilirubin &gt; 2.0fold upper normal limit ( UNL ) ; ALT AST &gt; 2.5fold UNL ) . In patient hepatic metastasis , value ALT AST 5fold UNL permit . Unpaired renal function ( creatinine &gt; 2.0 mg/dL ) . Pregnancy lactate . Treatment investigational agent previous 4 week . Second malignancy ( except cervix carcinoma situ skin carcinoma – melanoma adequate treatment ) . Previous malignancy allow diseasefree survival superior 5 year , except renal carcinoma melanoma . Males .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>Drug-resistant metastatic breast cancer</keyword>
</DOC>